Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088465 | 0.91 | SRD5A1 (0.31) | SRD5A1NPC1RAB9AF2AR | |
| SCHEMBL10088901 | 0.91 | SRD5A1 (0.42) | SRD5A1MAOBMAOA | |
| SCHEMBL10088529 | 0.90 | FOXM1 (0.33) | SRD5A1NPC1RAB9AF2 | |
| SCHEMBL10088458 | 0.85 | RAB9A (0.37) | SRD5A1NPC1RAB9AARMAOB | |
| SCHEMBL10310541 | 0.81 | EPHX2 (0.36) | NPC1RAB9AAR | |
| SCHEMBL10088904 | 0.80 | SRD5A1 (0.37) | SRD5A1ARMAOBMAOA | |
| SCHEMBL10088936 | 0.80 | ESRRA (0.41) | SRD5A1NPC1RAB9AMAOBMAOA | |
| SCHEMBL10088577 | 0.80 | SLC6A4 (0.34) | AR | |
| SCHEMBL10088640 | 0.77 | PTGER4 (0.36) | ARMAOB | |
| SCHEMBL10088534 | 0.77 | MAOA (0.31) | SRD5A1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | SRD5A1 397/4885NPC1 372/4885RAB9A 3084/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | SRD5A1 494/4885NPC1 271/4885RAB9A 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.